REGISTERED NUMBER: |
Unaudited Financial Statements |
for the Period 12 April 2023 to 31 July 2024 |
for |
Cogent Biosciences Ltd |
Trading as |
Convincente |
REGISTERED NUMBER: |
Unaudited Financial Statements |
for the Period 12 April 2023 to 31 July 2024 |
for |
Cogent Biosciences Ltd |
Trading as |
Convincente |
Cogent Biosciences Ltd (Registered number: 14797374) |
Trading as Convincente |
Contents of the Financial Statements |
for the Period 12 April 2023 to 31 July 2024 |
Page |
Company Information | 1 |
Balance Sheet | 2 |
Notes to the Financial Statements | 4 |
Cogent Biosciences Ltd |
Trading as Convincente |
Company Information |
for the Period 12 April 2023 to 31 July 2024 |
DIRECTORS: |
REGISTERED OFFICE: |
REGISTERED NUMBER: |
ACCOUNTANTS: |
Eldo House |
Kempson Way |
Suffolk Business Park |
Bury St Edmunds |
Suffolk |
IP32 7AR |
Cogent Biosciences Ltd (Registered number: 14797374) |
Trading as Convincente |
Balance Sheet |
31 July 2024 |
Notes | £ | £ |
FIXED ASSETS |
Tangible assets | 4 |
CURRENT ASSETS |
Debtors | 5 |
Cash at bank |
CREDITORS |
Amounts falling due within one year | 6 |
NET CURRENT ASSETS |
TOTAL ASSETS LESS CURRENT LIABILITIES |
PROVISIONS FOR LIABILITIES | 7 |
NET ASSETS |
CAPITAL AND RESERVES |
Called up share capital | 8 |
Retained earnings |
SHAREHOLDERS' FUNDS |
The directors acknowledge their responsibilities for: |
(a) | ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and |
(b) | preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company. |
Cogent Biosciences Ltd (Registered number: 14797374) |
Trading as Convincente |
Balance Sheet - continued |
31 July 2024 |
The financial statements were approved by the Board of Directors and authorised for issue on |
Cogent Biosciences Ltd (Registered number: 14797374) |
Trading as Convincente |
Notes to the Financial Statements |
for the Period 12 April 2023 to 31 July 2024 |
1. | STATUTORY INFORMATION |
Cogent Biosciences Ltd is a |
The presentation currency of the financial statements is the Pound Sterling (£). |
2. | ACCOUNTING POLICIES |
Basis of preparing the financial statements |
Turnover |
Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes. Income is recognised in the accounts when the company receives the right to receive consideration for services provided. |
Tangible fixed assets |
Computer equipment | - |
Financial instruments |
The company only enters into basic financial instrument transactions that result in recognition of financial assets and liabilities. Basic financial instruments are recognised at amortised cost. |
Taxation |
Taxation for the period comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity. |
Current or deferred taxation assets and liabilities are not discounted. |
Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date. |
Deferred tax |
Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date. |
Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the period end and that are expected to apply to the reversal of the timing difference. |
Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. |
Pension costs and other post-retirement benefits |
The company operates a defined contribution pension scheme. Contributions payable to the company's pension scheme are charged to profit or loss in the period to which they relate. |
Cogent Biosciences Ltd (Registered number: 14797374) |
Trading as Convincente |
Notes to the Financial Statements - continued |
for the Period 12 April 2023 to 31 July 2024 |
2. | ACCOUNTING POLICIES - continued |
Impairment |
At each reporting date, goodwill and other fixed assets, including tangible fixed assets and investments but excluding investment properties, are assessed to determine whether there is an indication that the carrying amount of an asset may be more than its recoverable amount and that the asset should be impaired. If there is an indication of possible impairment, the recoverable amount of an asset, which is the higher of its value in use and its net realisable value, is estimated and compared with its carrying amount. If the recoverable amount is lower, the carrying amount of the asset is written down to its estimated recoverable amount and an impairment loss is recognised in profit and loss. |
3. | EMPLOYEES AND DIRECTORS |
The average number of employees during the period was |
4. | TANGIBLE FIXED ASSETS |
Plant and |
machinery |
etc |
£ |
COST |
Additions |
At 31 July 2024 |
DEPRECIATION |
Charge for period |
At 31 July 2024 |
NET BOOK VALUE |
At 31 July 2024 |
5. | DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR |
£ |
Trade debtors |
6. | CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR |
£ |
Taxation and social security |
Other creditors |
Other creditors includes a directors loan. |
7. | PROVISIONS FOR LIABILITIES |
£ |
Deferred tax |
Accelerated capital allowances | 189 |
Cogent Biosciences Ltd (Registered number: 14797374) |
Trading as Convincente |
Notes to the Financial Statements - continued |
for the Period 12 April 2023 to 31 July 2024 |
7. | PROVISIONS FOR LIABILITIES - continued |
Deferred |
tax |
£ |
Charge to Income Statement during period |
Balance at 31 July 2024 |
8. | CALLED UP SHARE CAPITAL |
Allotted, issued and fully paid: |
Number: | Class: | Nominal |
value: | £ |
Ordinary shares | £1 | 150 |
Ordinary A shares | £1 | 50 |
200 |
The following shares were allotted and fully paid for cash at par during the period: |
150 Ordinary shares shares of £1 each |
50 Ordinary A shares shares of £1 each |